Vencilla Medtex LLP

API

Clopidogrel Bisulphate (form 1)

Clopidogrel Bisulphate (form 1) is listed in the Vencilla catalogue as an active pharmaceutical ingredient for business-to-business sourcing enquiries. It is a salt form of clopidogrel bisulphate. Molecular formula C16H18ClNO6S2; molecular weight 419.9 g/mol (PubChem CID 115366). Share the required grade, specification, quantity, documentation and destination market with your enquiry.

Product overview

Product type
API
Type
API
Vencilla ID
PRD-100246

Chemical identity

CAS number
120202-66-6
Molecular formula
C16H18ClNO6S2
Molecular weight
419.9 g/mol
Substance form
Salt form
Active moiety
Clopidogrel bisulphate (C16H16ClNO2S, 321.8 g/mol)
IUPAC name
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate;sulfuric acid
InChIKey
FDEODCTUSIWGLK-RSAXXLAASA-N

Technical specification

Product specifications (salt or form, grade and pack) are confirmed for each enquiry during qualification.

References

Reference information researched 2026-10-14.

Documentation

Documentation requirements are reviewed for each enquiry during qualification.

Market compliance

Regulatory, import and registration requirements depend on the destination market and the intended use, and are reviewed for each enquiry. This record does not indicate approval, registration or authorisation in any market.

Pharmaceutical sourcing disclaimer

Sourcing and qualification

  1. Search

    Find a product by name, therapeutic area or product class.

  2. Enquire

    Send a sourcing enquiry with strength, quantity, destination market and documentation needs.

  3. Qualify

    Vencilla reviews sourcing suitability, documentation and availability with qualified third-party supply partners.

  4. Quote and export

    Quotation and export coordination follow qualification.

NEXT STEP

Request a quote for this product

Tell us the strength, quantity, destination market and documentation you need. Availability and sourcing suitability are assessed during qualification.